Literature DB >> 22522326

Medical care for chronic-phase stroke in Japan.

Naoyuki Hattori1, Teruyasu Hirayama, Yoichi Katayama.   

Abstract

Stroke leaves serious neurological sequelae, which require long-term medical and social care, imposing financial and mental burdens on the patients and their families, and causing enormous losses to society. It is currently required that medical resources be used efficiently and the cost-effectiveness of treatment be analyzed carefully. We conducted a follow-up survey of stroke patients admitted to the hospital attached to our university in order to build a picture of the current status of chronic-phase stroke medical treatment. In total, 330 patients were analyzed in this study. We evaluated utility and medical cost at one year after onset. To investigate the relationship between activities of daily living (ADL) classified according to the modified Rankin scale (mRS) and quality of life (QOL), utility was calculated for each ADL level. Utility at 1 year post-onset for each mRS level was: ADL0, 0.89; ADL1, 0.79; ADL2, 0.65; ADL3, 0.58; ADL4, 0.36; and ADL5, 0.09. A significant correlation was seen between utility and mRS. Direct monthly medical costs at 1 year post-onset were 61,536 yen in the ADL0 group and 383,444 yen in the ADL5 group, indicating that a worse ADL score required higher medical costs. Direct monthly costs were significantly different between ADL levels. This present study has clarified the QOL and medical costs of chronic-phase stroke patients, and many cost-utility analyses will be based on our data in the future in Japan.

Entities:  

Mesh:

Year:  2012        PMID: 22522326     DOI: 10.2176/nmc.52.175

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  4 in total

1.  Disabled life expectancy with and without stroke: a 10-year Japanese prospective cohort study.

Authors:  Chi-Tsun Chiu; Vanessa Yong; Hsiao-Wen Chen; Yasuhiko Saito
Journal:  Qual Life Res       Date:  2019-07-15       Impact factor: 4.147

2.  Cost-Effectiveness Analysis of Initiating Type 2 Diabetes Therapy with a Sodium-Glucose Cotransporter 2 Inhibitor Versus Conventional Therapy in Japan.

Authors:  Ataru Igarashi; Keiko Maruyama-Sakurai; Anna Kubota; Hiroki Akiyama; Toshitaka Yajima; Shun Kohsaka; Hiroaki Miyata
Journal:  Diabetes Ther       Date:  2022-06-16       Impact factor: 3.595

3.  Cost-effectiveness analysis of patent foramen ovale closure versus medical therapy alone after cryptogenic stroke.

Authors:  Yoko Shijoh; Shota Saito; Zhehao Dai; Sachiko Ohde
Journal:  PLoS One       Date:  2022-06-03       Impact factor: 3.752

4.  Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation.

Authors:  Ataru Igarashi; Rei Goto; Kiyomi Suwa; Reiko Yoshikawa; Alexandra J Ward; Jörgen Moller
Journal:  Appl Health Econ Health Policy       Date:  2016-02       Impact factor: 2.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.